Renal Effects of Levosimendan: A Consensus Report

Clicks: 100
ID: 267199
2013
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Renal dysfunction is common in clinical settings in which cardiac function is compromised such as heart failure, cardiac surgery or sepsis, and is associated with high morbidity and mortality. Levosimendan is a calcium sensitizer and potassium channel opener used in the treatment of acute heart failure. This review describes the effects of the inodilator levosimendan on renal function. A panel of 25 scientists and clinicians from 15 European countries (Austria, Finland, France, Hungary, Germany, Greece, Italy, Portugal, the Netherlands, Slovenia, Spain, Sweden, Turkey, the United Kingdom, and Ukraine) convened and reached a consensus on the current interpretation of the renal effects of levosimendan described both in non-clinical research and in clinical study reports. Most reports on the effect of levosimendan indicate an improvement of renal function in heart failure, sepsis and cardiac surgery settings. However, caution should be applied as study designs differed from randomized, controlled studies to uncontrolled ones. Importantly, in the largest HF study (REVIVE I and II) no significant changes in the renal function were detected. As it regards the mechanism of action, the opening of mitochondrial KATP channels by levosimendan is involved through a preconditioning effect. There is a strong rationale for randomized controlled trials seeking beneficial renal effects of levosimendan. As an example, a study is shortly to commence to assess the role of levosimendan for the prevention of acute organ dysfunction in sepsis (LeoPARDS).
Reference Key
yilmaz2013cardiovascularrenal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mehmet B. Yilmaz;Elena Grossini;José C. Silva Cardoso;István Édes;Francesco Fedele;Piero Pollesello;Matti Kivikko;Veli-Pekka Harjola;Julia Hasslacher;Alexandre Mebazaa;Andrea Morelli;Jos le Noble;Anders Oldner;Ignacio Oulego Erroz;John T. Parissis;Alexander Parkhomenko;Gerhard Poelzl;Sebastian Rehberg;Sven-Erik Ricksten;Luís M. Rodríguez Fernández;Markku Salmenperä;Mervyn Singer;Sascha Treskatsch;Bojan Vrtovec;Gerhard Wikström;Mehmet B. Yilmaz;Elena Grossini;José C. Silva Cardoso;István Édes;Francesco Fedele;Piero Pollesello;Matti Kivikko;Veli-Pekka Harjola;Julia Hasslacher;Alexandre Mebazaa;Andrea Morelli;Jos le Noble;Anders Oldner;Ignacio Oulego Erroz;John T. Parissis;Alexander Parkhomenko;Gerhard Poelzl;Sebastian Rehberg;Sven-Erik Ricksten;Luís M. Rodríguez Fernández;Markku Salmenperä;Mervyn Singer;Sascha Treskatsch;Bojan Vrtovec;Gerhard Wikström;
Journal cardiovascular drugs and therapy
Year 2013
DOI
doi:10.1007/s10557-013-6485-6
URL
https://dx.doi.org/10.1007%2Fs10557-013-6485-6
Keywords
cardiology National Center for Biotechnology Information NCBI NLM MEDLINE review animals humans pubmed abstract nih national institutes of health national library of medicine Cardiotonic Agents / pharmacology* kidney / drug effects* simendan hydrazones / pharmacology* pyridazines / pharmacology* pmid:23929366 pmc3830192 doi:10.1007/s10557-013-6485-6 mehmet b yilmaz elena grossini gerhard wikström kidney / physiology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.